Related Experiment Video

Updated: Jul 10, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibitors for cancer therapy

Tae-You Kim1, Yung-Jue Bang, Keith D Robertson

  • 1National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. kimty@snu.ac.kr

Epigenetics
|November 14, 2007
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in cancer therapy by reversing epigenetic abnormalities and reactivating silenced genes. New research reveals their anti-tumor effects also involve non-histone protein acetylation.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Cancer epigenomes are characterized by DNA methylation and histone modifications.
  • Epigenetic abnormalities are common in tumors and potentially reversible.
  • Histone deacetylase inhibitors (HDACIs) are a promising class of epigenetic drugs for cancer treatment.

Purpose of the Study:

  • To review new insights into the molecular mechanisms of HDACIs.
  • To discuss the current clinical development status of HDACIs.
  • To explore potential future applications of HDACIs in cancer therapy.

Main Methods:

  • Review of current scientific literature on HDACIs and cancer.
  • Analysis of molecular mechanisms, including gene transcription and non-histone protein acetylation.
  • Summary of clinical trial data and therapeutic outcomes.

Main Results:

  • HDACIs reactivate silenced genes and exhibit selective anti-tumor effects in cancer cells.
  • HDACIs are generally well-tolerated with demonstrated anti-tumor activity.
  • Inhibition of non-histone protein acetylation is an emerging mechanism for HDACIs' anti-tumor effects.

Conclusions:

  • HDACIs represent a significant therapeutic strategy in oncology due to their epigenetic modulation.
  • Understanding novel mechanisms, such as non-histone protein acetylation, will enhance HDACIs' clinical utility.
  • Further clinical development and research into HDACIs hold promise for improved cancer treatment outcomes.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...